Aquestive Therapeutics prices $75M public offering of 16.7M shares at $4.50 per share

Aquestive Therapeutics, Inc.

Offering of 16,666,667 shares at $4.50 per share; gross proceeds ~$75M, net ~$69.8M.
Underwriters granted 30-day option to purchase up to 2,500,000 additional shares.
Proceeds to advance Anaphylm (epinephrine) sublingual film and Libervant (diazepam) buccal film.
Closing expected on or about March 22, 2024; Leerink Partners and Piper Sandler lead.
Company expects net proceeds plus existing cash to fund operations through December 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aquestive Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at $69.8 million net proceeds (effective 2024-03-19).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC and Piper Sandler & Co.
Value: $69.8 million net proceeds
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $4.50 per share.

View on SEC.gov

547 material agreements filed in the last 30 days. Browse all material agreements →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-014613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.